Challenges In Commercializing Inhaled Insulin

Corporation made a big splash last week with a press release announcing that its inhaled insulin product, Afrezza, had successfully completed two phase 3 clinical trials designed to support its New Drug Application (NDA) with the FDA. In Type 1 diabetes, Afrezza was shown to be non-inferior to ’s injected insulin, Novolog, with significantly less hypoglycemia. In patients with Type 2 diabetes treated with oral therapy, Afrezza compared to oral therapy alone was superior in reducing HbA1c levels and got more patients to target levels.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.